Aptose Biosciences Stock Price, News & Analysis (NASDAQ:APTO)

$2.80 -0.02 (-0.71 %)
(As of 01/19/2018 02:09 PM ET)
Previous Close$2.82
Today's Range$2.72 - $2.90
52-Week Range$0.78 - $2.94
Volume381,400 shs
Average Volume434,700 shs
Market Capitalization$80.71 million
P/E Ratio-4.24
Dividend YieldN/A
Beta2.55

About Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences logoAptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Receive APTO News and Ratings via Email

Sign-up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:APTO
CUSIPN/A
Phone+1-647-4799828

Debt

Debt-to-Equity RatioN/A
Current Ratio8.30%
Quick Ratio8.30%

Price-To-Earnings

Trailing P/E Ratio-4.24242424242424
Forward P/E Ratio-4.59
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.47 per share
Price / Book5.96

Profitability

Trailing EPS($0.66)
Net Income$-14,060,000.00
Net MarginsN/A
Return on Equity-129.12%
Return on Assets-111.84%

Miscellaneous

Employees23
Outstanding Shares26,370,000

Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc (NASDAQ:APTO) announced its earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. View Aptose Biosciences' Earnings History.

Where is Aptose Biosciences' stock going? Where will Aptose Biosciences' stock price be in 2018?

4 equities research analysts have issued twelve-month price targets for Aptose Biosciences' shares. Their forecasts range from $5.00 to $7.00. On average, they expect Aptose Biosciences' share price to reach $6.00 in the next year. View Analyst Ratings for Aptose Biosciences.

What are Wall Street analysts saying about Aptose Biosciences stock?

Here are some recent quotes from research analysts about Aptose Biosciences stock:

  • 1. According to Zacks Investment Research, "Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. " (1/16/2018)
  • 2. Canaccord Genuity analysts commented, "CATB reported 3/31 cash of $38.5MM, sufficient to fund operations into Q2:18." (5/12/2017)

Who are some of Aptose Biosciences' key competitors?

Who are Aptose Biosciences' key executives?

Aptose Biosciences' management team includes the folowing people:

  • William Glenn Rice, Chairman of the Board, President, Chief Executive Officer
  • Gregory Kwok Lee Chow, Chief Financial Officer, Senior Vice President
  • Denis R. Burger Ph.D., Independent Director (Age 70)
  • Erich M. Platzer M.D., Ph.D., Independent Director
  • Bradley Thompson, Independent Director
  • Mark D. Vincent M.D., Independent Director
  • Warren Whitehead, Independent Director

Who owns Aptose Biosciences stock?

Aptose Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (0.17%). View Institutional Ownership Trends for Aptose Biosciences.

Who bought Aptose Biosciences stock? Who is buying Aptose Biosciences stock?

Aptose Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View Insider Buying and Selling for Aptose Biosciences.

How do I buy Aptose Biosciences stock?

Shares of Aptose Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aptose Biosciences' stock price today?

One share of Aptose Biosciences stock can currently be purchased for approximately $2.80.

How big of a company is Aptose Biosciences?

Aptose Biosciences has a market capitalization of $80.71 million. The biotechnology company earns $-14,060,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. Aptose Biosciences employs 23 workers across the globe.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 5955 Airport Rd Suite 228, MISSISSAUGA, ON L4V 1R9, Canada. The biotechnology company can be reached via phone at +1-647-4799828 or via email at [email protected]


MarketBeat Community Rating for Aptose Biosciences (APTO)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  292
MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aptose Biosciences (NASDAQ:APTO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.752.60
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$6.00$7.67$9.00
Price Target Upside: 233.33% upside233.33% upside439.91% upside718.18% upside

Aptose Biosciences (NASDAQ:APTO) Consensus Price Target History

Price Target History for Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences (NASDAQ:APTO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/13/2017HC WainwrightReiterated RatingBuy -> Buy$4.00 -> $6.00HighView Rating Details
11/15/2017Canaccord GenuitySet Price TargetBuy$7.00N/AView Rating Details
10/23/2017Roth CapitalReiterated RatingBuy -> Buy$5.00N/AView Rating Details
6/8/2017Rodman & RenshawInitiated CoverageNeutral -> NeutralHighView Rating Details
11/16/2016Royal Bank of CanadaLower Price TargetOutperform$18.00 -> $12.00N/AView Rating Details
6/9/2016OppenheimerReiterated RatingBuyN/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Aptose Biosciences (NASDAQ:APTO) Earnings History and Estimates Chart

Earnings by Quarter for Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences (NASDAQ APTO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.13)($0.11)ViewN/AView Earnings Details
8/8/2017Q2($0.18)($0.11)ViewListenView Earnings Details
5/11/2017Q1 2017($0.19)ViewN/AView Earnings Details
3/28/2017Q4 2016($0.19)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.36)($0.24)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.32)($0.36)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.30)($0.31)ViewN/AView Earnings Details
3/29/2016Q415($0.28)($0.38)ViewN/AView Earnings Details
11/10/2015Q315($0.33)($0.27)ViewN/AView Earnings Details
8/4/2015Q215($0.31)($0.22)ViewN/AView Earnings Details
5/5/2015Q1 2015($0.31)($0.25)ViewN/AView Earnings Details
3/3/2015Q4 2014($0.31)($0.25)ViewN/AView Earnings Details
11/5/2014Q3 2014($0.32)ViewN/AView Earnings Details
7/15/2014Q2 2014($0.24)($0.48)ViewN/AView Earnings Details
4/10/2014Q1 2014($0.72)($0.48)ViewN/AView Earnings Details
1/7/2014Q4 2013($0.72)ViewN/AView Earnings Details
10/15/2013Q3 2013($0.36)ViewN/AView Earnings Details
7/15/2013Q2 2013($0.36)ViewN/AView Earnings Details
4/12/2013Q1 2013($0.36)ViewN/AView Earnings Details
1/14/2013Q4 2012($0.48)ViewN/AView Earnings Details
10/15/2012Q3 2012($0.36)ViewN/AView Earnings Details
8/8/2012Q2 2012$0.60ViewN/AView Earnings Details
4/12/2012Q1 2012($0.58)ViewN/AView Earnings Details
1/13/2012Q4 2011($0.82)ViewN/AView Earnings Details
11/11/2011Q3 2011($0.76)ViewN/AView Earnings Details
8/26/2011Q2 2011($0.73)ViewN/AView Earnings Details
1/14/2011Q4 2010($1.34)ViewN/AView Earnings Details
10/15/2010Q3 2010($1.38)ViewN/AView Earnings Details
8/30/2010Q2 2010($2.16)ViewN/AView Earnings Details
1/14/2009Q4 2008$4.41ViewN/AView Earnings Details
10/9/2008Q3 2008$3.24ViewN/AView Earnings Details
4/14/2008Q1 2008$6.49ViewN/AView Earnings Details
1/8/2008Q4 2007($4.69)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Aptose Biosciences (NASDAQ:APTO) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.61 EPS
Next Year EPS Consensus Estimate: $-0.75 EPS

Dividends

Dividend History for Aptose Biosciences (NASDAQ:APTO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aptose Biosciences (NASDAQ APTO)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Aptose Biosciences (NASDAQ APTO) News Headlines

Source:
DateHeadline
Aptose Biosciences (APTO) Stock Rating Lowered by Zacks Investment ResearchAptose Biosciences (APTO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 16 at 6:02 PM
Aptose Biosciences to Present at Biotech Showcase™ 2018 Conference - GlobeNewswire (press release)Aptose Biosciences to Present at Biotech Showcase™ 2018 Conference - GlobeNewswire (press release)
globenewswire.com - January 2 at 8:52 PM
Aptose Biosciences to Present at Biotech Showcase™ 2018 ConferenceAptose Biosciences to Present at Biotech Showcase™ 2018 Conference
finance.yahoo.com - January 2 at 11:10 AM
Mid-Afternoon Market Update: Crude Oil Down 0.8%; Kazia ... - BenzingaMid-Afternoon Market Update: Crude Oil Down 0.8%; Kazia ... - Benzinga
www.benzinga.com - December 27 at 6:09 PM
Mid-Morning Market Update: Markets Mostly Lower; Mallinckrodt To Buy Sucampo Pharmaceuticals For $18/Share - BenzingaMid-Morning Market Update: Markets Mostly Lower; Mallinckrodt To Buy Sucampo Pharmaceuticals For $18/Share - Benzinga
www.benzinga.com - December 26 at 3:23 PM
Mid-Afternoon Market Update: Crude Oil Up 2.5%; Aptose Biosciences Shares Spike Higher - BenzingaMid-Afternoon Market Update: Crude Oil Up 2.5%; Aptose Biosciences Shares Spike Higher - Benzinga
www.benzinga.com - December 26 at 3:23 PM
FDA Grants Orphan Drug Designation to Aptose Biosciences for CG ... - GlobeNewswire (press release)FDA Grants Orphan Drug Designation to Aptose Biosciences for CG ... - GlobeNewswire (press release)
globenewswire.com - December 26 at 3:23 PM
Aptose Biosciences Inc (APTO) Receives Consensus Rating of "Hold" from AnalystsAptose Biosciences Inc (APTO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - December 26 at 1:38 AM
Zacks Investment Research Upgrades Aptose Biosciences (APTO) to HoldZacks Investment Research Upgrades Aptose Biosciences (APTO) to Hold
www.americanbankingnews.com - December 25 at 5:53 PM
Aptose Biosciences (APTO) Lowered to Sell at Zacks Investment ResearchAptose Biosciences (APTO) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - December 15 at 8:38 PM
4 Top-Ranked Biotech Stocks Under $20 With Room for Growth - Nasdaq4 Top-Ranked Biotech Stocks Under $20 With Room for Growth - Nasdaq
www.nasdaq.com - December 14 at 11:41 AM
Aptose Biosciences (APTO) Stock Rating Reaffirmed by HC WainwrightAptose Biosciences (APTO) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - December 14 at 12:34 AM
Aptose Presents New Preclinical Data on CG806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting - GlobeNewswire (press release)Aptose Presents New Preclinical Data on CG'806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting - GlobeNewswire (press release)
globenewswire.com - December 13 at 11:45 AM
Aptose Biosciences, Inc. (APTO) Expected to Announce Earnings of -$0.12 Per ShareAptose Biosciences, Inc. (APTO) Expected to Announce Earnings of -$0.12 Per Share
www.americanbankingnews.com - December 13 at 1:30 AM
Aptose Biosciences (APTO) Downgraded by ValuEngine to Strong SellAptose Biosciences (APTO) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - December 3 at 11:40 PM
Aptose Biosciences, Inc. (APTO) Receives Consensus Recommendation of "Buy" from AnalystsAptose Biosciences, Inc. (APTO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 1 at 4:57 AM
BRIEF-Aptose Biosciences Files For Offering Of Up To 6 Mln Of Its Common Shares By The Selling ShareholderBRIEF-Aptose Biosciences Files For Offering Of Up To 6 Mln Of Its Common Shares By The Selling Shareholder
www.reuters.com - November 29 at 3:34 PM
Head-To-Head Analysis: TG Therapeutics (TGTX) & Aptose Biosciences (APTO)Head-To-Head Analysis: TG Therapeutics (TGTX) & Aptose Biosciences (APTO)
www.americanbankingnews.com - November 19 at 11:24 PM
Aptose Biosciences, Inc. (APTO) PT Set at $4.00 by HC WainwrightAptose Biosciences, Inc. (APTO) PT Set at $4.00 by HC Wainwright
www.americanbankingnews.com - November 19 at 6:20 PM
Aptose Biosciences, Inc. (APTO) Upgraded to "Buy" at Zacks Investment ResearchAptose Biosciences, Inc. (APTO) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 17 at 7:59 PM
Canaccord Genuity Analysts Give Aptose Biosciences, Inc. (APTO) a $7.00 Price TargetCanaccord Genuity Analysts Give Aptose Biosciences, Inc. (APTO) a $7.00 Price Target
www.americanbankingnews.com - November 17 at 12:56 AM
BRIEF-Aptose Biosciences Inc Q3 loss per share C$0.14BRIEF-Aptose Biosciences Inc Q3 loss per share C$0.14
www.reuters.com - November 14 at 4:26 PM
Aptose Biosciences Inc. to Host Earnings CallAptose Biosciences Inc. to Host Earnings Call
finance.yahoo.com - November 14 at 4:26 PM
Aptose Reports Results for the Third Quarter Ended September 30, 2017Aptose Reports Results for the Third Quarter Ended September 30, 2017
finance.yahoo.com - November 14 at 4:26 PM
Aptose Biosciences, Inc. (APTO) Given Average Recommendation of "Buy" by AnalystsAptose Biosciences, Inc. (APTO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 6 at 1:40 AM
Aptose To Present New CG806 Data At The 2017 ASH Annual MeetingAptose To Present New CG'806 Data At The 2017 ASH Annual Meeting
www.thestreet.com - November 3 at 9:19 AM
Aptose Biosciences (APTO) to Present New CG806 Data at ASHAptose Biosciences (APTO) to Present New CG'806 Data at ASH
www.streetinsider.com - November 1 at 4:31 PM
Aptose Biosciences (APTO) to Present New CG806 Data at ASHAptose Biosciences (APTO) to Present New CG'806 Data at ASH
www.streetinsider.com - November 1 at 4:31 PM
Aptose to Present New CG’806 Data at the 2017 ASH Annual MeetingAptose to Present New CG’806 Data at the 2017 ASH Annual Meeting
finance.yahoo.com - November 1 at 4:31 PM
Aptose Biosciences (APTO) Reports $15.5M Common Shares ... - StreetInsider.comAptose Biosciences (APTO) Reports $15.5M Common Shares ... - StreetInsider.com
www.streetinsider.com - October 31 at 3:03 AM
Aptose Enters into $15.5 Million Common Shares Purchase Agreement with Aspire Capital Fund, LLCAptose Enters into $15.5 Million Common Shares Purchase Agreement with Aspire Capital Fund, LLC
finance.yahoo.com - October 30 at 4:57 PM
Head-To-Head Review: Aptose Biosciences (APTO) & Regulus Therapeutics (RGLS)Head-To-Head Review: Aptose Biosciences (APTO) & Regulus Therapeutics (RGLS)
www.americanbankingnews.com - October 24 at 10:06 PM
Aptose Biosciences, Inc. (APTO) Expected to Post Earnings of -$0.12 Per ShareAptose Biosciences, Inc. (APTO) Expected to Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - October 17 at 2:30 PM
Aptose Biosciences, Inc. (APTO) Given Average Recommendation of "Buy" by BrokeragesAptose Biosciences, Inc. (APTO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 2:44 AM
How Does Aptose Biosciences Inc (TSX:APS) Compare To The Healthcare Sector?How Does Aptose Biosciences Inc (TSX:APS) Compare To The Healthcare Sector?
finance.yahoo.com - October 2 at 3:52 PM
-$0.12 Earnings Per Share Expected for Aptose Biosciences Inc (APTO) This Quarter-$0.12 Earnings Per Share Expected for Aptose Biosciences Inc (APTO) This Quarter
www.americanbankingnews.com - September 28 at 10:38 PM
Analyzing CytRx Corporation (CYTR) and Aptose Biosciences (APTO)Analyzing CytRx Corporation (CYTR) and Aptose Biosciences (APTO)
www.americanbankingnews.com - September 21 at 4:26 PM
Aptose Biosciences (APTO) versus Its Peers Financial AnalysisAptose Biosciences (APTO) versus Its Peers Financial Analysis
www.americanbankingnews.com - September 21 at 4:28 AM
Aptose to Present at the 17th Annual Biotech in Europe Forum ... - GlobeNewswire (press release)Aptose to Present at the 17th Annual Biotech in Europe Forum ... - GlobeNewswire (press release)
globenewswire.com - September 20 at 9:43 PM
Aptose Looking Toward Human Studies - Seeking AlphaAptose Looking Toward Human Studies - Seeking Alpha
seekingalpha.com - September 20 at 4:41 PM
Contrasting Icon Plc (ICLR) and Aptose Biosciences (APTO)Contrasting Icon Plc (ICLR) and Aptose Biosciences (APTO)
www.americanbankingnews.com - September 20 at 12:16 AM
Aptose to Present at the 17th Annual Biotech in Europe ForumAptose to Present at the 17th Annual Biotech in Europe Forum
finance.yahoo.com - September 19 at 3:59 PM
Aptose Biosciences, Inc. (APTO) Given Consensus Rating of "Buy" by BrokeragesAptose Biosciences, Inc. (APTO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 17 at 2:50 AM
PRA Health Sciences (PRAH) vs. Aptose Biosciences (APTO) Head-To-Head SurveyPRA Health Sciences (PRAH) vs. Aptose Biosciences (APTO) Head-To-Head Survey
www.americanbankingnews.com - September 16 at 4:24 AM
Is Aptose Biosciences Inc (TSX:APS) Undervalued?Is Aptose Biosciences Inc (TSX:APS) Undervalued?
finance.yahoo.com - September 13 at 5:08 PM
Biotech Stocks on Investors Radar -- PDL BioPharma, Progenics Pharma, Agenus, and Aptose BiosciencesBiotech Stocks on Investors' Radar -- PDL BioPharma, Progenics Pharma, Agenus, and Aptose Biosciences
www.prnewswire.com - September 13 at 2:18 AM
Aptose Biosciences (APTO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowAptose Biosciences (APTO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 2:18 AM
Aptose Biosciences (APTO), CrystalGenomics Announce Issuance of US Patent for CG806 - StreetInsider.comAptose Biosciences (APTO), CrystalGenomics Announce Issuance of US Patent for CG'806 - StreetInsider.com
www.streetinsider.com - September 12 at 4:13 PM
Aptose Biosciences, Inc. (APTO) Raised to "Buy" at HC WainwrightAptose Biosciences, Inc. (APTO) Raised to "Buy" at HC Wainwright
www.americanbankingnews.com - September 10 at 8:24 AM
Analyst Sees Near-Term Inflection Point For Aptose Biosciences, Upgrades Stock - BenzingaAnalyst Sees Near-Term Inflection Point For Aptose Biosciences, Upgrades Stock - Benzinga
www.benzinga.com - September 9 at 3:47 PM

SEC Filings

Aptose Biosciences (NASDAQ:APTO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aptose Biosciences (NASDAQ:APTO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aptose Biosciences (NASDAQ APTO) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.